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ABSTRACT
Autosomal dominant polycystic kidney disease (ADPKD) is an important cause of ESRD for which there
exists no approved therapy in the United States. Defective glucose metabolism has been identified as a
feature of ADPKD, and inhibition of glycolysis using glucose analogs ameliorates aggressive PKD in
preclinical models. Here, we investigated the effects of chronic treatment with low doses of the glucose
analog 2-deoxy-D-glucose (2DG) on ADPKD progression in orthologous and slowly progressive murine
models created by inducible inactivation of the Pkd1 gene postnatally. As previously reported, early in-
activation (postnatal days 11 and 12) of Pkd1 resulted in PKD developing within weeks, whereas late
inactivation (postnatal days 25–28) resulted in PKD developing in months. Irrespective of the timing
of Pkd1 gene inactivation, cystic kidneys showed enhanced uptake of 13C-glucose and conversion to
13C-lactate. Administration of 2DG restored normal renal levels of the phosphorylated forms of AMP–
activated protein kinase and its target acetyl-CoA carboxylase. Furthermore, 2DG greatly retarded dis-
ease progression in bothmodel systems, reducing the increase in total kidney volume and cystic index and
markedly reducing CD45–positive cell infiltration. Notably, chronic administration of low doses (100mg/kg
5 days per week) of 2DG did not result in any obvious sign of toxicity as assessed by analysis of brain and
heart histology as well as behavioral tests. Our data provide proof of principle support for the use of 2DG
as a therapeutic strategy in ADPKD.
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Autosomal dominant polycystic kidney disease
(ADPKD) is themost commonmonogenicdisorder
affecting the kidney,with an estimatedprevalence of
individuals affected at birth of 1 in 500 to1 in1000.1–3
The disease is caused by loss-of-function mutations
in either polycystic kidney disease 1 (PKD1; in 85%
of patients) or PKD2 (in the remaining 15%).1–3
ADPKD is a chronic condition caused by the
replacement of normal renal parenchyma by cysts,
eventually causing complete loss of renal function in
one half of the patients by the age of 50 years old.1–4
In recent years, several cascades were found
deregulated in the disease, leading to the identifica-
tion of potential therapeutic targets in preclinical
animal models.1–3,5–7 Among all of these opportu-
nities for therapy, the use of a vasopressin receptor
antagonist, Tolvaptan, is the only one that so far
resulted in an effective amelioration of disease
progression in patients,8–10 providing the first
opportunity for therapy.10 We and others have re-
cently shown that metabolic alterations can be
observed in animal models of PKD.11–14 In
particular, in a recent study, we have shown that
defective glucose metabolism is a feature of
ADPKD.11 Both cells and kidneys carrying inactiva-
tion of the Pkd1 gene were found to be addicted to
glucose and generate most of their energy needs
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(ATP) through aerobic glycolysis in a process resembling the
Warburg effect observed in cancer.11 Furthermore, analysis of
microarrays data generated from the cyst-lining epithelia in
patients with ADPKD1 showed a clear signature of increase
in the expression levels of genes involved in glycolysis and a
significant decrease in genes involved in the opposite process,
gluconeogenesis.11,12 These data suggest that enhanced glyco-
lytic rates might be present in the tissue from patients and that
this metabolic alteration might be targeted for therapy.11,12
Proof of concept studies on two distinct orthologous but
very aggressive disease models showed that a glucose analog
2-deoxy-D-glucose (2DG) could, in principle, halt the progres-
sion of the disease.11,12
Here, we show that chronic administration of low doses of
2DG(100mg/kg5days aweek)has the ability topreventdisease
progression in two slowly progressive, orthologous disease
models in the presence of no obvious signs of toxicity. The
results represent a proof of principle for this molecule to be
used as a potential therapeutic approach in patients affected by
ADPKD.
RESULTS
Enhanced Glycolysis in Two Slowly Progressive and
Orthologous Models of PKD
To address whether chronic administration of low doses of
2DG remains effective, we used orthologous and slowly
progressive disease models. Previous studies have shown
that early inactivation of the Pkd1 gene (before P13) results
in an aggressive PKD model, whereas inactivation after P14
results in a slowly progressive disease model.15,16 We
intercrossed a Tamoxifen–inducible Cre line (TmCre)17 with
mice harboring floxable Pkd1 alleles.18 A single injection of
Tamoxifen (10 mg/40 g) was performed at either P11 or P12,
and the cystic kidneys were collected 2 weeks later (hereafter
referred to as the medium-term model) (Figure 1A). In a sec-
ond set of experiments, Tamoxifen was injected at P25–P28,
and the kidneys were collected 3.5 months later (hereafter
referred to as the long-term model) (Figure 1A). For simplic-
ity, we refer to cystic mice (Pkd1DC/floxTmCre) or controls
(Pkd1flox/+TmCre; Pkd1flox/+ and Pkd1DC/flox) interchangeably.
Control animals were also injected with Tamoxifen at the in-
dicated times and analyzed in parallel.
We first tested if the cystic kidneys generated on time-
dependent inactivation of Pkd1 result in an increase in glucose
uptake as expected for highly glycolytic tissues and as we
previously reported.11 Injection of 13C-glucose in either the
medium– or the long–term animal model followed by analysis
of kidney lysates by nuclear magnetic resonance (NMR)
40minutes later revealed increased glucose uptake and increased
conversion to 13C-lactate in these tissues compared with con-
trol kidneys (Figure 1, B and C, Supplemental Figure 1A). On
the basis of these results, we concluded that these animals
should also be sensitive to the treatment with 2DG irrespective
of the time of Pkd1 inactivation. Next, we wondered whether
treatment in the presence of 2DG would further increase glu-
cose uptake as widely reported for cancers. Indeed, when
2DG (100 mg/kg) was administered to mice, we could
observe a significant increase in the total amount of glucose
(i.e., glucose + 2DG) taken up by the kidney (Figure 1D). Since
we previously reported an impairment in AMPK activation in
the Pkd1flox/2KspCremice, wewondered whether thismolecule
was altered in the slowly progressive PKD model as well. In-
deed, we found that AMPK activity is reduced in the long–term
mouse model (Figure 1E). Importantly, treatment with 2DG
restored the activation state of AMPK (Figure 1E) but had no
effect on the nuclear localization of pCREB, indicating that
2DG acts either on a different pathway or downstream of
cAMP (Figure 1F).
2DG Effectively Retards Disease Progression in the
Medium–Term PKD Model
Next, we tested the effect of treatment with 100mg/kg 2DG for
5 days aweek in themedium-termmodel. After 2weeks of 2DG
treatment, the kidneys appeared smaller than the vehicle-
treated ones (Figure 2A), and the kidney to body weight ratio
was significantly decreased compared with NaCl-treated ani-
mals (Figure 2B). Given that mice at this age are still growing,
we tested whether treatment in the presence of 2DG might
affect the growth curves of the animals, indicating some type
of possible toxicity problem. We found that the total body
weight of the animals was not affected by 2DG treatment in
either control or PKD animals (Supplemental Figure 1B). His-
tologic analysis followed by quantification of the cystic index
showed a marked reduction of the cystic burden in 2DG-
treated animals compared with NaCl-treated ones, suggesting
that the reduced kidney over body weight is indeed because
of a marked decrease in the expansion of renal cysts (Figure 2,
C and D).
2DG Effectively Retards Disease Progression in the
Long–Term PKD Model
Next, we tested if late-onset PKD (the long-term model
described in Figure 1A) could also be improved by the use of
100 mg/kg 2DG administered chronically for 5 days a week
followed by a 2-day washout tominimize potential side effects.
To follow the progression of the disease longitudinally in this
long–term animal model, after the injection of Tamoxifen at
P25, mice were followed up using in vivo magnetic resonance
imaging (MRI); 30 days after injection of Tamoxifen, the first
images of the kidneys were acquired (T=0), and the treatment
was initiated immediately after (Figure 3A). Only litters con-
taining at least two Pkd1Dc/fTmCre and one control were used
for further analysis. Littermate mutant or control animals
were treated with either 2DG (100 mg/kg 5 days a week) or
vehicle only (NaCl); 55 (T=1M) or 85 (T=2M) days after in-
activation (corresponding to 1 or 2 months of treatment),
kidney volume was calculated by three-dimensional (3D) seg-
mentation of in vivo MRI images (Figure 3, B and C), and
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Figure 1. The Warburg effect the Pkd1 inducible KO model irrespective of the inactivation timepoint and effects of 2DG. (A) Schematic
view of the experimental plan. Medium-term model (left panel): Pkd1DC/floxTmCre mice were injected with a single dose of Tamoxifen
(10 mg/40 g) at either P11 or P12, and kidneys were collected at P25 or P26, respectively. Long-term model (right panel): Pkd1DC/floxTmCre
mice were injected with a single dose of Tamoxifen (10 mg/40 g) at P25–P28, MRI was performed after 1, 2, and 3 months, and kidneys
were finally collected 2 weeks after the last MRI. (B and C) Comparison of 13C enrichment on control and mutant mice. Representative
1H-1D spectra of the long-term experiment showing the 13C satellite pattern of the 13C-glucose (Ha) and 13C-lactate (CbH3) in control (blue)
and cystic mice (red) in the long-term model. The two sets of spectra were acquired with the same spectral parameters and normalized to
dry weight, such that the peak intensity of individual resonances is directly comparable. (C) The percentage of 13C-glucose and 13C-lactate
enrichment (calculated as described in Concise Methods) was higher in the kidneys from the cystic mice (Pkd1DC/floxTmCre) compared with
those in the controls (Pkd1flox/+TmCre; Pkd1flox/+ and Pkd1DC/flox interchangeably) as calculated from multiple samples acquired as in B. (D)
The percentage of the total amount of glucose (glucose and 2DG) taken up by the kidneys of mice treated with 2DG (100 mg/kg) was
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blood was withdrawn from the tail. Notably, in this long-term
model, we chose to initiate the 2DG treatment when the kid-
neys were already cystic and enlarged in size (Figure 3, A–C,
Supplemental Table 1), but their function was not yet
compromised, reasoning that this would be the condition in
which patients affected by ADPKD would start therapy.
Despite the fact that the therapy was initiated when the
kidneys were already enlarged and grossly cystic, monitoring
showed a marked reduction in the increase of total kidney
volume (TKV) of animals treated with 2DG compared with
NaCl at both 1 and 2 months after treatment (Figure 3, A–C,
Supplemental Table 1). Analysis of BUN at the different time
points revealed that the functionality of the kidneys in this
animal model is maintained for a relatively long period of
time when the kidneys appear morphologically compromised,
similar to what seems to occur in patients (Figure 3, C andD).1
Importantly, 2DG–treated PKD animals tend to have a better
preservation of renal function compared with vehicle-treated
animals (Figure 3D), although we observed a more pro-
nounced improvement in the TKV than in the renal function
(Figure 3, C and D).
Two weeks after the last MRI, mice were euthanized and
analyzed. The kidneys derived from 2DG-treated animals
appeared much smaller than those extracted from vehicle-
treated animals (Figure 3E), and in line with the MRI data,
kidney over body weight of 2DG-treated animals was signifi-
cantly reduced compared with that of mice treated with
vehicle only (Figure 3, E and F). Of interest, we observed
that there is a good linear correlation between the TKV
and the kidney over body weight parameter in these animals
(r2=0.95) (Figure 3G).
2DG Improves the Cystic Index and Inflammatory
Response in the Long–Term PKD Model in the Absence
of Obvious Signs of Toxicity
Furthermore, histologic analysis revealed a significant reduc-
tion in cystic index in 2DG-treatedmice compared with NaCl-
treated ones (Figure 4, A and B, Supplemental Figure 1C).
Importantly, we used real-time PCR for CD15 (granulocytes),
CD68 (macrophages), and CD45 (leukocyte common anti-
gen) to evaluate the infiltration in these kidneys. We
noticed a very prominent infiltration rate in the cystic tissues
for all of these three markers, in line with previous studies.19
Of interest, 2DG significantly reduced the levels of CD45-
expressing cells as assayed both by RT-PCR and immunohis-
tochemistry (Figure 4, C andD). The reduced infiltration rates
might reflect a reduced tissue damage in the long–term PKD
model. Alternatively, these results might suggest that 2DG
counteracts tissue infiltration in addition to slowing down
cystic epithelia proliferation.
In a previous study, we showed that 2DG limits the
expansion of cysts specifically induced in the distal tubule/
collecting ducts by a KspCre line.11 In this model, we observe
the presence of cysts of different origin, as previously reported
Figure 2. Treatment with 2DG ameliorates cystic kidney disease in
the medium-term model. (A) Images of cystic kidneys treated with
2DG at 100mg/kg or NaCl from P12 to P26 and littermates controls.
The best example is shown (litter 2). (B) The percentage of kidney
weight to total body weight in cystic mice treated as described in A
was significantly reduced compared with the vehicle control (NaCl).
The same treatment had no effect on the percentage of kidney to
total body weight in control mice. The power of the study was 0.94.
(C) Representative images of the histologic analysis of kidneys
treated as described in A. (D) Cystic index calculated for the kidneys
from Pkd1DC/floxTmCre mice treated with 2DG or vehicle as de-
scribed in A–C. Means6SEMs are indicated. NS indicates P$0.05.
Scale bars, 4 mm in A; 1 mm in C. *P,0.05 determined using the
Mann–Whitney test for B and D; **P,0.01 determined using the
Mann–Whitney test for B and D.
significantly increased. (E) pAMPKT172 and its target pAcetyl-CoACarboxylase (pACC) S69were downregulated in cystic kidneys treated
with vehicle compared with control and restored after 2DG treatment. (F) Nuclear pCREB staining is observed in the DBA-positive cysts in
both 2DG–treated and untreated cystic kidneys. Scale bar, 50 mm in F. *P,0.05 determined using the unpaired t-test. D.O.B., day of birth.
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Figure 3. Treatment with 2DG retards PKD progression in the long-term model. (A) Follow-up of kidneys in vivo using MRI in the long–
term animal model. Both cystic (Pkd1DC/floxTmCre) and control (Pkd1flox/+TmCre; Pkd1flox/+ and Pkd1DC/flox interchangeably) animals
were injected with a single dose of Tamoxifen (10 mg/40 g) at P25/P28 followed by treatment with either vehicle (NaCl) or 2DG at
100 mg/kg. Representative images acquired by MRI as described in Concise Methods are shown. The first MRI was acquired 1 month
after injection of Tamoxifen before initiation of treatment (T=0), and the second and third MRIs were acquired 1 (T=1M) and 2 (T=2M)
months later, respectively. (B) Three-dimensional reconstruction of the kidneys from the left and right kidneys 1 (red), 2 (orange), and 3
months (white) after injection. (C) TKV was calculated for the cystic and control kidneys treated with 100 mg/kg 2DG or vehicle only at
each of the time points described in A. The volume of the 2DG–treated cystic kidneys is significantly reduced both 1 and 2 months after
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(Supplemental Figure 1D). Of interest, treatment with 2DG
did not change the percentage of cysts of different origin, sug-
gesting that the molecule is equally active on cysts of every
tubular segment (Supplemental Figure 1D). Thus, we used
Lotus Tetragonolobus Lectin (LTL; VECTOR) staining to
test if cysts of proximal tubule origin also respond to 2DG
treatment. Indeed, LTL-positive cysts are smaller in volume
on 2DG treatment compared with NaCl-treated kidneys
(NaCl: 3.2310360.53103 mm2, n=48; 2DG: 2.831036
0.33103 mm2; mean6SEM; n=160 from three different lit-
ters), suggesting that 2DG effectively retards cyst expansion in
both the distal and collecting ducts and the proximal tubules.
Importantly, 2DG treatment had no significant effect on the
total body weight in either controls or PKD animals (Figure
4E). Notably, additional biochemical parameters, including
liver toxicity markers (alanine amino transferase, aspartate
aminotransferase, and alkaline phosphatase), revealed that
no obvious sign of toxicity could be appreciated (Figure 4, F
and G, Supplemental Figure 1E). These results are in line with
previous reports describing that low doses of 2DG adminis-
tered chronically in animal models are well tolerated and do
not cause toxicity.20,21 However, one study has reported signs
of toxicity in the heart when high doses of 2DG are ingested by
the rat.22 Thus, we designed a study similar to the one con-
ducted in the cystic animals on wild-type mice with the aim of
testing the toxicity of this compound in our conditions (i.e.,
intraperitoneal administration of 100 mg/kg 5 days a week for
2.5 months). In these animals, we did not observe any major
sign of kidney toxicity (measured as BUN), liver toxicity (mea-
sured as alanine amino transferase, aspartate aminotransfer-
ase, lactate dehydrogenase, and albumin), or heart toxicity
(CK) (Supplemental Table 2). In these animals, we also ob-
served no difference in body weight, food and water intake, or
body temperature (Supplemental Figure 2) as well as the levels
of circulating glucose and insulin (Supplemental Figure 3, A
and B). In particular, we focused our attention on tissues
highly depending on glucose, such as heart and brain, to de-
termine whether they might be affected by our treatment reg-
imen. These animals were subjected to behavioral tests
followed by histologic analysis. First, mice were subjected to
the flag-visible version of the water maze test to assess visual
ability in 2DG–treated wild–type mice (n=8) and nontreated
mice (n=6). Both groups had normal visual ability (ANOVA
repeatedmeasures for treatment effect on the time to reach the
flagged platform F[1,12]=0.11; P=0.74). Second, mice were
subjected to the standard hidden platform version of the water
maze.23 Of great interest, the 2DG-treated mice were more
efficient in the time to reach the platform during the trials
(Figure 4H) (ANOVA repeated measures for escape latency
F[1,12]=8.8; P=0.01 with no interaction between treatment3
days F[1,14]=1.05; P=0.40), which was also shown by the sig-
nificant difference in the pathway to reach the platform (Sup-
plemental Figure 3C). No differences between the two groups
during probe trial in crossing the former goal annulus could be
observed (Figure 4I) (ANOVA repeated measures for annulus
crossing F[1,12]=0.18; P=0.68). Third, mice were subjected to
the spontaneous alternation test to assess working memory.
2DG treatment has no effect on working memory (Supple-
mental Figure 3, E and F). These results suggest that 2DG
administration tends to improve spatial memory acquisition
but has no effect on the working memory. These data are of
great interest and will require further investigation. Impor-
tantly, all other parameters analyzed, includingmotility scored
by speed ofmovement, were not affected by 2DG (Supplemen-
tal Figure 3D). At the completion of the experiment, animals
were euthanized and analyzed at the histologic level. Hearts
did not appear to be grossly altered at the histologic level in
these animals, and no vacuolization could be observed (Figure
4J). Similarly, histologic analysis of brains did not reveal any
major problem (Figure 4J). Quantification of the hippocampal
region and cortical thickness normalized by the total brain
area did not reveal morphologic alterations (NaCl hip mean,
0.052 mm2 6SEM [0.002]; 2DG hip mean, 0.050 mm2 6SEM
[0.004]; NaCl cortical thickness, 893.4mm6SEM [48.5]; 2DG
cortical thickness, 904.5 mm 6SEM [118.8]).
DISCUSSION
Our study shows that 2DG effectively slows down disease
progression in orthologous and mild PKD mice models and
that it does so irrespective of the window of time in which the
Pkd1 gene is inactivated. These results suggest that inhibition
of glycolysis in ADPKD might be effective in early as well as
late disease manifestations. Furthermore, our data show that
2DG at low doses has no obvious toxicity effects even on
chronic administration, in line with previous studies.20,21
However, some controversies on the effects of 2DG adminis-
tration have been reported in the literature. Chronic ingestion
for 6 months of high doses of 2DG (250 mg/kg per day) were
reported to cause mortality and heart vacuolization in the
rat.22 On the contrary, a second study reported that chronic
treatment. Thepowerof the studywas0.93. (D)BUNwasevaluatedon thebloodwithdrawn from the tails of theanimals at each timepoint in
whichMRIs were acquired plus at euthanasia 2 weeks after the lastMRI, showing a trend to renal function improvement in cystic animals on
2DG treatment compared with vehicle–treated (NaCl) cystic animals. (E) Images of cystic and control kidneys treated as described above
and collected 2 weeks after the last MRI show a significant reduction of volume after 2DG treatment. The best example is shown. (F)
Percentage of kidney weight to total body weight in the cystic or control mice treated as described above. (G) Graph showing the relation
between the kidney to total body weight versus the TKV evaluated byMRI shows a linear correlation (r2=0.95). NS indicates P$0.05. Scale
bars, 1 cm in A and B; 5mm in E. *P,0.05 determined using theMann–Whitney test for C and F; ***P,0.001 determined using theMann–
Whitney test for C and F.
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Figure 4. Treatment with 2DG ameliorates cystic kidney disease in the long-term model without evident signs of toxicity. (A) Rep-
resentative histologic pictures of treated cystic (Pkd1DC/floxTmCre) kidneys as defined in Figure 1A with 2DG or vehicle (NaCl) only
reveal a marked reduction in cystic burden in the 2DG-treated kidneys. (B) Cystic index evaluated in kidneys from cystic (Pkd1DC/floxTmCre)
animals treated with either 2DG or vehicle (NaCl) only as described in A. (C) Key inflammation genes were upregulated in untreated
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intraperitoneal injections of even higher doses (500 mg/kg per
day) did not cause major toxicity in the rat.20 In this study, we
show that low doses of 2DG (100 mg/kg) injected intraperitone-
ally for 5 days a week followed by 2 days of washout for 2.5
months did not cause any apparent sign of toxicity. Although
the route of administrationmight be the reason for these discrep-
ancies, in light of the studies in rats, some caution should be used,
and additional long–term studies should be pursued to establish
the possible toxicity of this compound and the optimal route of
administration. Importantly, our study indicates that the benefi-
cial effects seem more prominent in the long–term, chronically
treated PKD model, even if 2DG administration was initiated in
cystic and grossly enlarged kidneys. Because this resembles the
stage of ADPKD in which patients are selected for a potential
intervention, we speculate that 2DGwould be effective in retard-
ing disease progression in humans aswell, where increased lactate
accumulation has been reported, further suggesting that defective
glycolysis is likely to be present in patients.11,24 Importantly, 2DG
proved effective in retarding cyst expansion in both distal tubules
and collecting ducts and cysts of proximal tubule origin.
In conclusion, the efficacy, low toxicity, and capability to
reduce the expansion of cysts of all origins make 2DG a good
candidate for further testing in humans affected by ADPKD.
This molecule is well tolerated25,26 and might offer important
advantages overmolecules such as Tolvaptan, which has action
that is limited to cysts originating from specific segments of
the nephron (distal tubules and collecting ducts).10 Further-
more, we speculate that 2DG might be active in cysts origi-
nating in other organs, such as the bile ducts in the liver or
pancreatic cysts, because glucose transporters are ubiquitous.
With respect to this, it will be interesting to test if enhanced
glycolysis is a feature of these cysts as well.
Despite the potential advantages listed above, it should be
considered that 2DG is not currently approved for any human
condition, and additional toxicity studies on long administra-
tion should be performed. Finally, the fact that 2DG seems to
restore pAMPK levels but not the nuclear localization of
pCREB suggests that enhanced glycolysis is either a parallel
pathwayor activateddownstreamof cAMP. Itwill be important
to perform additional studies to distinguish between these two
possibilities, because these data might indicate that combina-
tion therapy between Tolvaptan and 2DG might offer an
additional opportunity to achieve a further beneficial effect.
CONCISE METHODS
Mouse Lines
We crossed C57/BL6 Pkd1DC/+mice18 to TmCre B6.Cg-Tg(CAG-cre/
Esr1*)5Amc/J mice (stock 004682; Jackson Laboratories). The prog-
eny C57/BL6 TmCre Pkd1DC/+ was bred with C57/BL6 Pkd1flox/flox
mice to produce the mice used in these studies. Cre recombinase
activity was induced by a single injection of Tamoxifen at P11 or
P12 for the medium-term model or P25/P28 for the long-term
model. Tamoxifen (catalog no. T5648; 10 mg/40 g; Sigma-Aldrich)
freshly prepared and dissolved in corn oil (catalog no. C8267; Sigma-
Aldrich) by continuous shaking at 37°C for 4 hours was injected in-
traperitoneally. For all animal care and experimental protocols, a
specific protocol was approved (IACUC 548) by the Institutional
Care and Use Ethical Committee at the San Raffaele Scientific Insti-
tute and further approved by the Italian Ministry of Health. For all
animal work, the female to male ratio was 1:1, and mice were ran-
domized for each experiment.
2DG Treatment
For treatments, mice were injected intraperitoneally with 2DG
(catalog no. D6134; Sigma-Aldrich) or vehicle (NaCl) once daily
for 5 consecutive days a week from P12 to P27 for the medium term
and fromP25/P28 to P130 for the long term at 100mg/kg bodywt. For
the long-term model, five different litters were used (Supplemental
Table 1).
Statistical Analyses
We calculated the statistical significance of differences using Mann–
Whitney or unpaired t test using GraphPad Prism (version 5.0). For
calculation of the power of the studies, for themedium-term animals,
cystic (Pkd1DC/floxTmCre) comparedwith control kidneys.With 2DG, a trend of reduction (CD15 andCD68) or significant reduction (CD45)
could be observed. Hprt expression was used as a normalizer for total cell number. (D) Immunohistochemistry confirmed a significant
reduction in the number of CD45-positive cells per acquired field (3503435 mm) in 2DG–treated cystic kidneys compared with NaCl-
treated tissues; ten fields were acquired in one renal medial section from three different animals. (E) 2DG treatment had no significant
effect on the total body weight in either controls or mutant mice. (F) Alanine aminotransferase (ALT) and (G) aspartate aminotransferase
(AST) values showed no liver toxicity induced by 2DG in any of the animals used. (H) During the standard hidden platform version of the
water maze trials, 2DG-treated mice were faster to reach the hidden platform (escape latency) compared with the vehicle-treated lit-
termates. (I) No differencewas observed in the annulus crossing during the probe trial in the first day (first 30 seconds) of the reversal phase.
Old goal (og) indicates the old platform position, old opposite (oo) specifies the newopposite position of the platform, and old left (ol) and
old right (or) show the quadrant at the left and the right of the old goal, respectively. (J) Representative images of heart sections of NaCl-
(n=6) and 2DG-treated (n=9) mice stained with Hematoxylin-Eosin showing absence of vacuolization caused by 2DG (upper panel).
Representative brain coronal sections (5 mm) of NaCl (n=5) and 2DG-treated (n=6) mice stained with Hematoxylin-Eosin show absence of
differences (lower panel). Cortical thickness (CC) and the hippocampal region (Hip) are indicated.NS indicates P$0.05. Scale bars, 100mm
in J, upper panel; 1mm in J, lower panel. *P,0.05 determined using theMann–Whitney test for B andD, t test for C, andANOVA for H and
I; **P,0.01 determined using the Mann–Whitney test for B and D, t test for C, and ANOVA for H and I; ***P,0.001 determined using the
Mann–Whitney test for B and D, t test for C, and ANOVA for H and I.
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we used as an end point, kidney/body weight. For this study, the
sample sizes were eight (for the NaCl-treated mice) and ten (for
the 2DG-treated mice). These groups achieve 94% power (0.94) to
detect a difference of 2.10 between the null hypothesis that both
group means are 8.90 (NaCl) and the alternative hypothesis that
the mean of group 2 is 6.80 (2DG), with known group SDs of 1.27
and 1.02, respectively, and a significance level (a) of 0.05000 using a
two–sided Mann–Whitney test assuming that the actual distribution
is normal.
For the long-term study,we usedTKVs at 2months of treatment as
an end point. Group sample sizes of seven (NaCl) and nine (2DG)
achieve 93% power to detect a difference of 1.23 between the null
hypothesis that both group means are 4.04 and the alternative
hypothesis that themean of group 2 is 2.81, with known group SDs of
0.59 and 0.74, respectively, and a significance level (a) of 0.05000
using a two–sided Mann–Whitney test assuming that the actual dis-
tribution is normal. For behavioral studies, ANOVA with repeated
measures was used for statistical analysis (StatView; SAS Institute,
Cary, NC).
NMR Acquisition and Data Analyses
P20 and P130 mutant mice (Pkd1DC/floxTmCre induced with Tamox-
ifen at P12 and P25/P28, respectively) and the control littermates
(Pkd1flox/+TmCre and Pkd1flox/+) were starved for 5–10 hours and
then injected intraperitoneally with 1000 mg/kg body wt 13C
uniformly labeled glucose (catalog no. CC850P10; Cortecnet); 40
minutes after the injection, the mice were euthanized, and their
kidneys were weighted, immediately frozen in liquid nitrogen,
and lyophilized for 24 hours. After lyophylization, kidneys were
weighted again to obtain their dry weights. Polar metabolites were
extracted from tissues using classic MeOH/CHCl3 solvent extrac-
tion strategy.27 Polar phases were lyophilized for 24 hours and
subsequently resuspended in 150 mM phosphate buffer with the
addition of 100 mM DSS as internal chemical shift reference and
sodium azide (0.02%) for sample preservation. Final volumes were
250 ml with D2O (100%).
NMR spectra were recorded at 25°C on a Bruker Avance 600 Ultra
Shield TM Plus 600-MHz Spectrometer equipped with triple-
resonance cryoprobe and pulsed field gradients. 1H-1D NMR spectra
(noesypr1d) were recorded with an acquisition time of 2 seconds, a
recycle time of 6 seconds to minimize peak saturation, and 256 and
1024 transients for long- andmedium-termmice, respectively. 1H-1D
NMR spectra were typically processed with zero filling to 131,000
points and apodized with an unshifted Gaussian and a 0.5-Hz line
broadening exponential. The spectra were carefully phased and base-
plane corrected before peak integration.
The global spectrumdeconvolution algorithm implemented in the
Mnova9.0 software package of Mestrelab was used to deconvolve and
integrate the spectra.28
To confirm glucose and 13C positional isotopomers, 2D-1H
TOCSY and 1H-13C HSQC experiments were also acquired. TOCSY
spectra were acquired with a standard pulse sequence with a mixing
time of 60 ms, 512 increments, and 40 or 56 transients for long- and
medium-term mice, respectively; 2D 1H-13C HSQC spectra were ac-
quired with a total of three transients for each of 400 increments.
Spectral widths were set to 12 and 185 ppm for 1H and 13C, respec-
tively (offsets at 4.7 and 75 ppm, respectively).
The 13C enrichment of glucose was determined integrating and
deconvolving the appropriate 1H13C satellites (at 5.36 and 5.08 ppm)
and the 1H12C peak (5.25 ppm), corresponding to the Ha anomeric
proton in the 1D-1H NMR spectra. Lactate13C enrichment was de-
termined considering the 1H13C satellites (at 1.42 and 1.22 ppm) and
the 1H12C peak at 1.31 ppm, corresponding to the methyl proton of
lactate in the 1H-1D NMR spectra. The percentage of 13C abundance
of labeled metabolites was calculated from the ratio of the peak areas
of the satellite peaks to the total peak intensity according to the equa-
tion F=I13C_satellites/I13C_satellites+I12C_central peak, where I is the peak
area.29,30We observed that the satellite at 5.36 ppmwas often difficult
to deconvolve because of partial overlap with the allantoin peak; its
integral value was, therefore, obtained from the symmetric satellite
peak at 5.08 ppm.
MRI
AllMRI studieswere performedon a 7-TPreclinical Scanner (BioSpec
70/30 USR, Paravision 5.1; Bruker) equipped with 450/675 mT/m
gradients (slew rate: 3400–4500 T/m per second; rise time: 140 ms)
and a circular polarized mouse body volume coil with an inner di-
ameter of 40 mm. Mice were under general anesthesia obtained by
1.5%–2% isoflurane vaporized in 100% oxygen (flow of 1 L/min).
Breathing and body temperature were monitored during MRI (SA
Instruments, Inc., Stony Brook, NY) and maintained around 30
breaths per minute and 37°C, respectively.
All MRI studies included axial and coronal RARE T2–weighted
sequences (slice thickness, 0.6mm; interslice gap, 0mm)with a num-
ber of slices, allowing a complete coverage of both kidneys.
Manual segmentation of the kidneys was performed on each slice,
excluding the collecting system and kidney volume results from
automatic summation of voxel volumes (OsiriX, version 5.6, 32 bit;
Pixmeo SARL). Five litters were used (A–E), including three control
mice treated with vehicle, six control mice treated with 2DG, seven
cystic mice treated with vehicle, and nine cystic mice treated with
2DG. Both acquisition and analysis of the data were performed
blindly by an operator unaware of genotype or treatment conditions.
The data generated by analysis of all animals used in the study are
included in Supplemental Table 1. For 3D reconstruction, the kidneys
were manually segmented on eachMRI slice using Mipav (Centre for
Information Technology, National Institutes of Health, Bethesda,
MD), and correspondent 3D surfaces were generated and visualized
using Paraview (Kitware, Inc., New York, NY). Each kidney surface
was aligned to the first MRI time point on the basis of the renal pelvis
location.
Clinical Chemistry
Analysis of serum samples was assessed by ILab Aries, a bench-top
analyzer that can perform photometry, turbidimetry, and potenti-
ometry tests (Instrumentation Laboratory, Werfen Group, Milan,
Italy).All parametersweredetectedusing kits and controls suppliedby
ILab Aries. Standard controls were run before each determination to
monitor the precision throughout the experiment, and the values
obtained for controls were always within the expected ranges.
1966 Journal of the American Society of Nephrology J Am Soc Nephrol 27: 1958–1969, 2016
BASIC RESEARCH www.jasn.org
Histology
After euthanasia, kidneys were washed in PBS, weighed, and fixed in
4% paraformaldehyde (catalog no. P6148; Sigma-Aldrich). After
incubation in a sucrose in PBS gradient scale from 10% to 30%,
samples were incubated in 10% glycerol (catalog no. G5150; Sigma-
Aldrich) in amixture of optimal cutting temperaturemedium (Killik;
catalog no. 05–9801; BIO-OPTICA) and 30% sucrose and then em-
bedded in OCT. Cryostat sections were air dried for 1 hour, rehydra-
ted in PBS, incubated in 1:10 Harris Hematoxylin (catalog no.
HHS16; Sigma-Aldrich) for 2 minutes, washed, and incubated in
Eosin Y (catalog no. 05–10002/L; BIO-OPTICA) for 7 minutes. Sec-
tions were finally washed again, dehydrated, and mounted in DPX
Mountant (catalog no. 44581; Sigma-Aldrich) for histology.
For brain and heart histology, organs were harvested directly after
euthanasia in zinc-formalin and transferred into 70% ethanol 24 hours
later. Tissues were then processed, embedded in paraffin, and stained;
sections (5 mm) were dewaxed, hydrated through a graded decrease
alcohol series, and stained for Hematoxylin-Eosin (BIO-OPTICA).
Bright-field imageswere acquired through anAperio Scanscope System
AT2 Microscope and an ImageScope program (Leica Biosystem)
following the manufacturer’s instructions. For quantifications of the
brain histology, four slices for each mouse were analyzed from Bregma
21.225 mm to Bregma22.55 mm. Cortical area was analyzed at32.5
enlargement, and the hippocampal area and the cortical thickness were
analyzed at 35 enlargement. The software used for the analyses was
Aperio ImageScope v12.1.0.5029 (Leica Biosystem). Statistical analyses
were made with GraphPad Prism (version 5.0).
Cystic Index
Images of longitudinal sections from the inner part of the kidney after
Hematoxylin-Eosin staining were taken (Nikon Eclipse E600 Micro-
scope, Nikon Digital Camera DXM1200, and ACT-1 software). The
ImageJ program (http://rsb.info.nih.gov/ij/) was then used to quantify
the total surface of the kidney and the total cystic area using 5000 mm2
as a cutoff to include a cyst. We next calculated the ratio between the
cystic area and the total area of the kidney.
Antibodies Lectins
Anti–pAcetyl-CoA Carboxylase (Ser79) 07–303 at 1:1000, anti-
pAMPK (Thr172) 40H9 2535 at 1:1000, anti-pCREB (Ser133; 87G3)
9198 at 1:400 were from Cell Signaling Technology. Antivinculin 05–
386 (clone V284) was from Millipore at 1:10,000. Lectin Dolichos
Biflorus Agglutinin (DBA) (VECTOR) and LTL were used at 1:100.
LTL/DBA Staining
Kidneys were harvested, fixed, and cut as described above for
histology. Sections were rehydrated; permeabilized with 0.1% PBS-
Triton X-100; blocked with PBS, 3%BSA, and 5% normal goat serum
for 1 hour; and incubated overnight with Lectin DBA and LTL diluted
at 1:100. After washingwith PBS, sectionsweremountedwithMowiol
with 49,6-Diamidine-29-phenylindole dihydrochloride (DAPI). At
least five pictures of sections of each kidney from mice of four litters
(four kidneys treated with 2DG and four kidneys treated with NaCl)
were obtained using an Axiophot Microscope (Carl Zeiss), and the
area of each cyst was quantified using ImageJ software.
Western Blot Analysis
For Western blot analysis, kidneys were smashed on dry ice and
resuspended in lysis buffer (10 mM Hepes, 10 mM KCl, 1.5 mM
MgCl2, 0.34 M sucrose, 1 mM dithiothreitol, 10% glycerol [pH 7.9],
0.1% Triton X-100, complete protease inhibitors [Roche], and phos-
phatase inhibitors; 1 mM final concentration of glycerophosphate,
sodium orthovanadate, and sodium fluoride). After centrifugation,
we separated the supernatant and the pellet. The supernatant was
clarified by a second centrifugation. We resolved proteins in an
SDS-PAGE gel and transferred them onto polyvinylidene fluoride
membranes. Next, we used 5% milk in Tris-buffered saline and
Tween 20 for blocking and secondary antibody incubations, and
3% BSA in Tris-buffered saline and Tween 20 was used for incuba-
tions with primary antibodies. We visualized horseradish peroxidase
(HRP) –conjugated secondary antibodies (anti-rabbit HRP linked
[NA934V] 1:10,000 and anti-mouse HRP linked [NXA931]
1:10,000; GE Healthcare) using the ECL System (Amersham).
Immunofluorescence
For immunofluorescence, kidneys were air dried for 30 minutes,
washed in PBS, permeabilized in PBS and Triton X-100 (0.1%),
blocked with 3% BSA in PBS, incubated overnight at 4°C with the
antibody to CD45 or pCREB in blocking solution, washed, and in-
cubated with the secondary antibody Alexa Fluor 488 anti-rat and
anti-rabbit (A21441; Invitrogen) for 1 hour. For the p-CREB immu-
nofluorescence, DBAwas incubated together with the secondary an-
tibody.
Real–Time PCR Analysis
We isolated total RNA from whole kidneys using the EuroGOLD
TriFast Kit (Euroclone) and obtained cDNA using oligo(dT) primers
(Invitrogen) and Superscript II Reverse Transcription (Invitrogen).
We performed quantitative real–time PCR in duplicates using Light-
Cycler480 (RocheMolecular Diagnostics) using SYBRGreen IMaster
Mix.
The primers used were the following: mCD45: forward: 5-
GAGGTGGGTGTGGATGAACT-3, reverse: 5-GTTGGATCGCTCCTG-
GAATA-3; mCD45: forward: 5-GGAGACCAGGAAGTCTGTGC-3,
reverse: 5-GTTCTGGGCTCCTTCCTCTT-3; mCD68: forward:
5-CTGACAAGGGACACTTCGGG-3, reverse: 5-AGGCCAATGAT-
GAGAGGCAG-3; and Hprt: forward: 5-TTATGTCCCCCGTT-
GACTGA-3, reverse: 5-ACATTGTGGCCCTCTGTGTG-3.
Water Maze Task and Spontaneous Alternation Test
Animals were maintained on a reversed 12-hour light/dark cycle at
22°C–24°C. Food and water were available ad libitum in the home
cage. All behavioral procedures were approved by the Animal Care of the
San Raffaele Scientific Institute and the National Ministry of Health
(IACUC 653). All of the behavioral tests were assessed on 3-month-old
mice comparing 2DG–treated and nontreated wild–type mice.
The hidden platform version of the water maze was used to test
spatial referencememory.23 Visual ability was tested in the flag-visible
version for four consecutive trials in 1 day. Spontaneous alternation
task was used to measure hippocampus–dependent spatial working
memory in a nonfood-rewarded task. A mouse was released in the
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central hub of a cross maze (four arms) and left free to explore for 10
minutes. Number and sequence of arm entries were recorded. A cor-
rect alternation was considered when no more than one repetition
over five entries was made.
During all tests, animals were videotracked using the EthoVision
2.3 System (Noldus Information Technology, Wageningen, The
Netherlands), with an image frequency of 4.2 per second. Raw data
were transferred to Wintrack 2.4 for offline analysis.
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A	   Pkd1ΔC/flox	   control	   2DG	   /	   0.42 0.39 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   NaCl	   /	   1.56 3.80 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   2DG	   /	   1.32 2.58 
B	   Pkd1flox	  /+:	  TmCre	   control	   NaCl	   0.38 0.49 0.56 
	   Pkd1ΔC/flox	   control	   2DG	   0.28 0.34 0.35 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   NaCl	   0.79 1.72 3.91 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   2DG	   0.61 1.21 3.23 
C	   Pkd1flox	  /+	   control	   2DG	   0.36 0.36 0.41 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   NaCl	   1.19 2.48 3.71 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   NaCl	   0.83 2.65 3.61 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   2DG	   1.19 2.24 3.70 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   2DG	   1.19 2.31 3.37 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   2DG	   0.60 1.10 2.27 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   2DG	   0.59 1.30 3.01 
D	   Pkd1ΔC/flox	   control	   NaCl	   0.43 0.46 0.49 
	   Pkd1ΔC/flox	   control	   2DG	   0.60 0.67 0.70 
	   Pkd1flox	  /+	   control	   2DG	   0.32 0.32 0.33 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   NaCl	   1.18 2.26 4.14 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   NaCl	   1.31 2.79 5.32 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   2DG	   1.02 1.46 2.24 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   2DG	   0.71 1.00 1.41 
E	   Pkd1HA/+:	  TmCre	   control	   NaCl	   0.42 0.47 0.48 
	   Pkd1flox	  /+	   control	   2DG	   0.37 0.38 0.42 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   NaCl	   0.91 1.92 3.78 
	   Pkd1ΔC/flox:	  TmCre	   cystic	   2DG	   1.01 2.22 3.49 
	  	  
Supplementary Table 1. Measurements of kidney volume by MRI of each long-term animal 
model employed in the study. a. Animals are shown within the individual litters. 5 independent 
litters were employed for the studies divided in A to E; b. the precise genotype of each animal 
employed in the study is shown; c. the phenotype classified as control (non cystic) or cystic kidneys 
are indicated; d. the type of treatement 2-deoxy-D-glucose (2DG) or vehicle only (NaCl) is 
indicated; e.  total kidney volumes were calculated in cm3 at the different timepoints: T=0, prior to 






















































































Supplementary Table 2: Biochemical parameters at various timepoints after long-term 2DG 
treatment as compared to NaCl treatment. Blood Urea Nitrogen (BUN), alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), lactate deshydrogenase-P (LDH-P), 
albumin (ALB) and creatine kinase (CK) were measured in the sera collected at P55, P85 and P130 








Supplementary Figure 1 
a. The percentage of 13C-glucose and 13C-lactate enrichment (calculated as described in Materials 
and Methods) was higher in the kidneys from the cystic mice from the medium-term model as 
described in Figure 1a. b. Growth curve from mice treated with 2DG or vehicle during the 
medium-term-experiment. c. Histology of kidney sections from four litters collected from long term 
model treated with 2DG or vehicle. d. Percentage of cyst that stain positive for DBA, LTL or 
negative for both (X) in the long-term PKD model treated with NaCl or 2DG. No significant 
differences in the origin of cyst distribution could be observed, suggesting that 2DG acts equally on 
all cysts. e. Alkaline Phosphatase (ALP) concentration of the serum collected at the same time point 
of the first (T=0), second (T=1M) and third (T=2M) MRI (one, two and three months after 
tamoxifen induction) of the long term experiment. 
 
Supplementary Figure 2: 2DG treatment has no systemic effects. Body weight (a), food intake 
(b), water intake (c) and body temperature (d) were not altered in males (left) and females (right) 
after treatment with 100 mg per kg 2DG 5 days a week for 2.5 months.  
 
Supplementary Figure 3: 2DG treated mice show no differences in glucose and insulin levels 
and normal motor ability and working memory. a-b. Analysis of glucose (a) or insulin (b) levels  
at the different time points in mice treated with 2DG or NaCl show no differences in circulating 
insulin or glucose levels. c. Improved pathway to reach the platform in the 2DG treated versus NaCl 
treated animals in the Morris water maze test was observed (ANOVA repeated measures for 
pathway F[1, 12]=9.7, p=0.0009 with no interaction between treatment*days F[1, 14]=0.9, p=0.5). 
d. No differences were observed between groups during the water maze test in the speed 
(F[1,12]=1.15, p=0.3). e-f. Spontaneous alternation test was performed to assess short-term working 
memory. No differences between 2DG and vehicle treated mice were observed for the number of 
visits (F[1,12]=0.4, p=0.53) (e) and for the percentage of correct alternations (F[1,12]=0.23, 
p=0.63) (f). Data points and bars represent the mean +/- SEM in from a to d. Histograms represent 
the mean ± SEM in e and f.	  
 
 
 
	  
